CVS HEALTH CORP

CVS Health Corporation Q1 2026: 1,803 holders, $76.5B in institutional value. The quarter is defined by significant OUTFLOW from four large institutional holders. BlackRock $9.0B (125.9M shares) -- despite a share INCREASE (+4.1M, +5.5M reported as INCREASED but valueChange -$559M). Vanguard total $7.8B across two entities: Capital Management $5.9B (82.7M shares, NEW position) + Portfolio Management $1.9B (26.0M shares, NEW). Capital World Investors $5.5B (77.2M shares, +1.5% share increase BUT valueChange +$178M). State Street $4.3B (59.3M shares, -1.4%, -$516M). Dodge & Cox $3.7B (51.8M shares, -19.8%, -$1.24B) -- the largest seller this quarter, cutting position by a quarter. FMR/Fidelity $2.2B (31.2M shares, -25.1%, -$1.01B, a major reduction from 41.0M prior shares). Geode Capital $2.1B (29.5M shares reported INCREASED but valueChange -$188M). JPMorgan $2.1B (29.5M shares, -3.0%, -$405M). Morgan Stanley $1.3B (17.8M shares, -12.5%, -$337M). Invesco $1.8B (25.1M shares reported INCREASED with valueChange -$101M, suspicious). Wells Fargo $626M (8.7M shares, NEW position, +$65M). Capital International Investors $1.1B (15.4M shares, -39.4%, -$1.08B). Goldman Sachs $1.0B (14.6M shares, +1.7%, +$248M). Charles Schwab IM $983M (13.7M shares, -0.8%, -$117M). Pzena Investment Management $989M (13.8M shares, -15.9%, -$247M). Davis Selected Advisers $879M (12.2M shares, -1.0%, -$134M). Northern Trust $836M (11.6M shares, -0.9%, -$103M). Legal & General $683M (9.5M shares reported INCREASED with valueChange -$55.4M). Ameriprise $643M (9.0M shares, +0.05%, +$4M). Amundi $529M (7.4M shares, +1.1%, +$67M). New positions: Vanguard two NEW, Wells Fargo NEW. Sellers: Dodge & Cox -$1.24B (sharpest), Capital International -$1.08B, FMR -$1.01B, State Street -$516M, JPMorgan -$405M, Morgan Stanley -$337M, Pzena -$247M, Capital Research Global slight, Invesco suspicious, Davis -$134M, Northern Trust -$103M, Goldman +$248M, Capital World +$178M, Amundi +$67M, Wells Fargo +$65M, Ameriprise flat. Buyers: Capital Research Global +$482M (largest buy), Capital World Investors +$178M, Amundi +$67M, Ameriprise flat, Wells Fargo +$65M (new). SMART-MONEY READ: CVS Q1 2026 is BEARISH-TO-MIXED. The three biggest sellers (Dodge & Cox -$1.24B + Capital International -$1.08B + FMR -$1.01B = $3.3B total out) represent strategic rotation, not noise -- all three are value-active shops with long CVS records. That all three reduced simultaneously in Q1 2026 reads as a consensus de-weighting of healthcare provider/retail-pharmacy exposure ahead of the PBM (pharmacy benefit management) restructuring and potential 2026-2027 patent cliff news flow. Capital Research Global's $482M add is the largest buy but doesn't offset the breadth of the sell-cohort. Net: the quarterly flow is negative; healthcare allocation preference is shifting. The presence of two Vanguard NEW entries at $7.8B total may partly offset this mechanically, but these are passive index entries, not active conviction.